2nd Quarter - Report

HARMONY BIOSCIENCES for HARMONY BIOSCIENCES

Firm
Client
Income
—
Expenses
$250,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

- Issues related to the development of therapies for rare diseases. - H.R.3, Elijah E. Cummings Lower Drug Costs Now Act; - H.R.6000, Cures 2.0 Act; - FY2022 Budget Reconciliation (H.R.5376); - H.R.5585, Advanced Research Project Agency-Health Act; - H.R.6963, Accelerated Approval Integrity Act of 2022; - H.R.7667, Food and Drug Amendments of 2022; - S.4348, FDASLA Act of 2022 - Issues relative to formulary placement of non-scheduled treatments

LobbyistCovered position, as disclosed
CATE MCCANLESS —
GEOFFREY WERTH —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 3 (117th), S. 4348 (117th), H.R. 6963 (117th), H.R. 5585 (117th), H.R. 7667 (117th), H.R. 6000 (117th), H.R. 5376 (117th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.